Please login to the form below

Not currently logged in
Email:
Password:

DMO

This page shows the latest DMO news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment

vein occlusion ( CRVO), diabetic macular oedema ( DMO), and myopic choroidal neovascularisation (mCNV).

Latest news

  • NICE backs Bayer's Eylea in diabetic eye condition NICE backs Bayer's Eylea in diabetic eye condition

    DMO). The eye condition affects around 189, 000 people with diabetes in the UK and is a thickening of the central part of the retina that can lead to irreversible vision ... For DMO Eylea is given as a 2mg intravitreal injection every month for five

  • Roche, Novartis and Bayer gain NICE recommendations Roche, Novartis and Bayer gain NICE recommendations

    In the draft final appraisal determination NICE recommends Eylea for the treatment of patients with diabetic macular oedema (DMO) - a condition that affects around 50, 000 people in the UK. .

  • NICE recommends Ozurdex for diabetic eye condition NICE recommends Ozurdex for diabetic eye condition

    The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the dexamethasone intravitreal implant for the treatment of diabetic macular oedema (DMO). ... The eye indication was approved for DMO in the EU in

  • Novartis launches another localised NHS eye service in UK Novartis launches another localised NHS eye service in UK

    The new services in Coventry provides care for conditions such as wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular oedema (DMO) or visual impairment due to

  • Germany's IQWiG delivers bad news for Bayer’s Eylea Germany's IQWiG delivers bad news for Bayer’s Eylea

    Eylea (aflibercept) has been sold in Germany for diabetic macular oedema (DMO) since August, but the German Institute for Quality and Efficiency in Health Care (IQWiG) now says it provides no ... The G-BA had earlier decided that Eylea would be compared

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics